Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin

W. J. Sandborn, R. H. Wiesner, W. J. Tremaine, Nicholas F La Russo

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Thirty five adult patients with precirrhotic primary sclerosing cholangitis were randomly allocated to treatment for at least one year with low dose (4.1 mg/kg/day) cyclosporin or placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/mild, moderate, or severe using the Truelove and Witt's criteria. Before treatment there were no differences between the cyclosporin and placebo groups in the number of patients with remission/mild colitis, 14/16 (88%) v 9/10 (90%), and moderate colitis, 2/16 (12%) v 1/10 (10%). During treatment, a remission/mild disease course was present in 15/16 (94%) v 6/10 (60%), p = 0.05 and a moderate disease course in 1/16 (6%) v 4/10 (40%), p = 0.05. It is concluded that patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and from fewer flares of remission/mildly active colitis. These findings suggest that cyclosporin may be of benefit to the colon in patients with ulcerative colitis who are being treated with cyclosporin for primary sclerosing cholangitis.

Original languageEnglish (US)
Pages (from-to)242-246
Number of pages5
JournalGut
Volume34
Issue number2
StatePublished - 1993

Fingerprint

Sclerosing Cholangitis
Ulcerative Colitis
Cyclosporine
Colitis
Placebos
Therapeutics
Colectomy
Inflammatory Bowel Diseases
Endoscopy
Colon

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. / Sandborn, W. J.; Wiesner, R. H.; Tremaine, W. J.; La Russo, Nicholas F.

In: Gut, Vol. 34, No. 2, 1993, p. 242-246.

Research output: Contribution to journalArticle

Sandborn, W. J. ; Wiesner, R. H. ; Tremaine, W. J. ; La Russo, Nicholas F. / Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. In: Gut. 1993 ; Vol. 34, No. 2. pp. 242-246.
@article{569a05a76f37424981bab58261ea9d0d,
title = "Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin",
abstract = "Thirty five adult patients with precirrhotic primary sclerosing cholangitis were randomly allocated to treatment for at least one year with low dose (4.1 mg/kg/day) cyclosporin or placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/mild, moderate, or severe using the Truelove and Witt's criteria. Before treatment there were no differences between the cyclosporin and placebo groups in the number of patients with remission/mild colitis, 14/16 (88{\%}) v 9/10 (90{\%}), and moderate colitis, 2/16 (12{\%}) v 1/10 (10{\%}). During treatment, a remission/mild disease course was present in 15/16 (94{\%}) v 6/10 (60{\%}), p = 0.05 and a moderate disease course in 1/16 (6{\%}) v 4/10 (40{\%}), p = 0.05. It is concluded that patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and from fewer flares of remission/mildly active colitis. These findings suggest that cyclosporin may be of benefit to the colon in patients with ulcerative colitis who are being treated with cyclosporin for primary sclerosing cholangitis.",
author = "Sandborn, {W. J.} and Wiesner, {R. H.} and Tremaine, {W. J.} and {La Russo}, {Nicholas F}",
year = "1993",
language = "English (US)",
volume = "34",
pages = "242--246",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin

AU - Sandborn, W. J.

AU - Wiesner, R. H.

AU - Tremaine, W. J.

AU - La Russo, Nicholas F

PY - 1993

Y1 - 1993

N2 - Thirty five adult patients with precirrhotic primary sclerosing cholangitis were randomly allocated to treatment for at least one year with low dose (4.1 mg/kg/day) cyclosporin or placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/mild, moderate, or severe using the Truelove and Witt's criteria. Before treatment there were no differences between the cyclosporin and placebo groups in the number of patients with remission/mild colitis, 14/16 (88%) v 9/10 (90%), and moderate colitis, 2/16 (12%) v 1/10 (10%). During treatment, a remission/mild disease course was present in 15/16 (94%) v 6/10 (60%), p = 0.05 and a moderate disease course in 1/16 (6%) v 4/10 (40%), p = 0.05. It is concluded that patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and from fewer flares of remission/mildly active colitis. These findings suggest that cyclosporin may be of benefit to the colon in patients with ulcerative colitis who are being treated with cyclosporin for primary sclerosing cholangitis.

AB - Thirty five adult patients with precirrhotic primary sclerosing cholangitis were randomly allocated to treatment for at least one year with low dose (4.1 mg/kg/day) cyclosporin or placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/mild, moderate, or severe using the Truelove and Witt's criteria. Before treatment there were no differences between the cyclosporin and placebo groups in the number of patients with remission/mild colitis, 14/16 (88%) v 9/10 (90%), and moderate colitis, 2/16 (12%) v 1/10 (10%). During treatment, a remission/mild disease course was present in 15/16 (94%) v 6/10 (60%), p = 0.05 and a moderate disease course in 1/16 (6%) v 4/10 (40%), p = 0.05. It is concluded that patients treated with cyclosporin for primary sclerosing cholangitis who have coexisting ulcerative colitis have a more benign course of colitis resulting both from improvement of moderately active colitis and from fewer flares of remission/mildly active colitis. These findings suggest that cyclosporin may be of benefit to the colon in patients with ulcerative colitis who are being treated with cyclosporin for primary sclerosing cholangitis.

UR - http://www.scopus.com/inward/record.url?scp=0027537517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027537517&partnerID=8YFLogxK

M3 - Article

C2 - 8432481

AN - SCOPUS:0027537517

VL - 34

SP - 242

EP - 246

JO - Gut

JF - Gut

SN - 0017-5749

IS - 2

ER -